Long COVID in Patients with HIV: Module 2

Target Audience

This activity is intended for infectious disease and HIV specialists engaged in the care of patients with HIV.

Program Description

Long COVID is becoming increasingly common as the pandemic continues. Patients with HIV who have had COVID-19 have a higher risk for developing long COVID, emphasizing the importance of vaccination and prevention in these patients. Though there is still insufficient knowledge about treating long COVID, there are guidelines for evaluation of long COVID and multiple existing management strategies that can help treat long COVID in patients with HIV. Drs. Onyema Ogbuagu and Michael Peluso discuss the risk of long COVID in patients with HIV, long COVID evaluation, existing management strategies, and the importance of HIV care in the face of long COVID.

Educational Objectives

After completing this activity, the participant should be better able to:

• Implement optimal approaches to caring for people with HIV coinfected with another viral infection

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Integritas Communications.  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

PACE designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Disclosure of Conflicts of Interest

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Onyema Ogbuagu, MBBCh, FACP, FIDSA: Consulting Fees: Gilead Sciences, Inc., ViiV Healthcare. Advisory Board: Janssen Pharmaceuticals, Inc.

Michael Peluso, MD, MPhil, MHS, DTM&H: Consulting Fees, Advisory Board, Speakers Bureau: AstraZeneca, Gilead Sciences, Inc. Data and Safety Board (DSMB) Member for HIV Cure Clinical Trial: American Gene Technologies

The PACE planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Instructions to Receive Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a minimum score of 100% on the posttest, and complete the program evaluation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Fee Information

There is no fee for this educational activity.

CME Questions – PACE Contact Information

For information about the accreditation of this program, please contact PACE https://partnersed.com/

Integritas Contact Information

For all other questions regarding this activity, please contact Integritas via email at info@exchangecme.com.